-
Company Insights
New![]()
Innovation and Patenting activity of Prometheus Biosciences Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Prometheus Biosciences Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Net Present Value Model: Prometheus Biosciences Inc’s PR-200
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRA-052 in Ulcerative Colitis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PRA-052 in Ulcerative Colitis Drug Details: PRA-052 is under development for the treatment of...
-
Company Profile
![]()
Prometheus Biosciences Inc – Company Profile
Prometheus Biosciences Inc (Prometheus Biosciences) is the biotech company that discover, develops and commercializes novel therapeutic and companion diagnostic product candidates for inflammatory bowel disease (IBD). The company’s pipeline products include PRA023, an anti-TL1A mAb for the treatment of ulcerative colitis and crohn’s disease, and PR600, PR300, PR1100, PR1800 and PR2100 against inflammatory bowel disease (IBD). It utilizes Prometheus360, a medicine platform that combines machine learning-based analytical process to develop its products. Prometheus Biosciences is also investigating therapeutics for gastrointestinal...
Add to Basket -
Product Insights
![]()
Therapeutic Drug Monitoring Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Therapeutic Drug Monitoring Pipeline Market Report Overview Therapeutic drug monitoring tests include reagents and test kits intended to measure different types of therapeutic drugs from samples ranging from serum/blood, urine, hair and sweat. The therapeutic drug monitoring pipeline market research report provides comprehensive information about the Therapeutic drug monitoring pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segments ·      Immunosuppressant Therapeutic Drug Monitoring...
-
Product Insights
![]()
Prometheus Biosciences Inc Pipeline Insight and Competitive Landscape, 2023
Prometheus Biosciences Inc (Prometheus Biosciences) is the biotech company that discover, develops and commercializes novel therapeutic and companion diagnostic product candidates for inflammatory bowel disease (IBD). The company’s pipeline products include PRA023, an anti-TL1A mAb for the treatment of ulcerative colitis and crohn’s disease; and PR600, PR300, PR1100, PR1800 and PR2100 against inflammatory bowel disease (IBD). It utilizes Prometheus360, a medicine platform that combines machine learning-based analytical process to develop its products. Prometheus Biosciences is also investigating therapeutics for gastrointestinal...
-
Product Insights
![]()
Prometheus Laboratories Inc Pipeline Insight and Competitive Landscape, 2023
Prometheus Laboratories Inc (Prometheus), a subsidiary of Nestle Health Science SA, is a drug development company that develops pharmaceutical and diagnostic products. The company provides medicine for the treatment of serologic and genetics test for celiac disease, TPMT testing, thiopurine monitoring, and Crohn’s disease, among others. It also markets and delivers proprietary diagnostic testing services, pharmaceutical products, and scientific nutritional solutions. Prometheus offers its products under various categories such as diagnostics, therapeutics, oncology and others. The company also provides materials...
-
Product Insights
![]()
Net Present Value Model: PR-200
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model PR-200 Drug Details PRA-023 is under...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRA-023
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PRA-023 Drug Details PRA-023 is under development for the treatment of inflammatory bowel diseases...
-
Product Insights
![]()
Auto-Immune Diseases Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
The Auto-Immune Diseases pipeline market research report provides comprehensive information about the Auto-Immune Diseases pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
![]()
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer,...
-
Product Insights
![]()
Crohn’s Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Crohn’s Disease (Regional Enteritis) pipeline market research report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease...
-
Product Insights
![]()
Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant. Global Markets Direct’s report features investigational drugs from across globe. The Systemic Sclerosis (Scleroderma) - Drugs In Development research report provides a comprehensive overview on the therapeutics  under  development  for  Systemic  Sclerosis  (Scleroderma),  complete  ...
-
Consumer Insights
![]()
KOL Perspectives: Implementation of the treat-to-target approach in IBD
› This KOL Insight briefing focuses on KOLs views of implementation of the treat-to-target approach in IBD
-
Sector Analysis
![]()
PharmaPoint: Irritable Bowel Syndrome(IBS) – Global Drug Forecast and Market Analysis to 2026
Irritable bowel syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. IBS is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least three months. IBS is classified into three main subtypes, according to the predominant bowel habit: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed-presentation (IBS-M) IBS. The IBS treatment landscape remains largely underserved, and ample opportunity exists for pharmaceutical companies to address the...
-
Sector Analysis
![]()
OpportunityAnalyzer: Vasculitis – Opportunity Analysis and Forecast to 2024
Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behçet's disease (BD). In 2014, there were 137,603 and 82,501 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan),...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.